The lung as a privileged site for the beneficial actions of PGE2.
about
Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptorsFeedback amplification of fibrosis through matrix stiffening and COX-2 suppressionInteraction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells.Resolution of Inflammation: What Controls Its Onset?Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathologyRegulation of immune responses by prostaglandin E2E-type prostanoid receptor 4 (EP4) in disease and therapyPost-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomalleiBoswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical dataLipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic TargetsNickel and the microbial toxin, MALP-2, stimulate proangiogenic mediators from human lung fibroblasts via a HIF-1alpha and COX-2-mediated pathwaySoluble iron modulates iron oxide particle-induced inflammatory responses via prostaglandin E(2 )synthesis: In vitro and in vivo studies.Repeated bouts of moderate-intensity aerobic exercise reduce airway reactivity in a murine asthma model.Interaction of apoptotic cells with macrophages upregulates COX-2/PGE2 and HGF expression via a positive feedback loop.Grape seed pro-anthocyanidins ameliorates radiation-induced lung injury.Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cellsA maladaptive role for EP4 receptors in mouse mesangial cells.Tulathromycin exerts proresolving effects in bovine neutrophils by inhibiting phospholipases and altering leukotriene B4, prostaglandin E2, and lipoxin A4 productionRegulation of COX-2 expression by miR-146a in lung cancer cellsProstaglandin E2 prevents hyperosmolar-induced human mast cell activation through prostanoid receptors EP2 and EP4.Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity.Selective eicosanoid-generating capacity of cytoplasmic phospholipase A2 in Pseudomonas aeruginosa-infected epithelial cells.Distinct protein kinase A anchoring proteins direct prostaglandin E2 modulation of Toll-like receptor signaling in alveolar macrophages.Role of the prostaglandin E2/E-prostanoid 2 receptor signalling pathway in TGFβ-induced mice mesangial cell damage.Prostaglandin (PG)E2 exhibits antifibrotic activity in vocal fold fibroblasts.Stimulation of protease-activated receptor-2 inhibits airway eosinophilia, hyperresponsiveness and bronchoconstriction in a murine model of allergic inflammation.Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development.Cyclooxygenase-2 signaling in vocal fold fibroblastsProstaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction.Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulationAge-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice.The alveolar macrophage: the forgotten cell in asthma.Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3.Activation of EP4 receptors prevents endotoxin-induced neutrophil infiltration into the airways and enhances microvascular barrier function.G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation.Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection.Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection.Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers.Cyclooxygenase-1 overexpression decreases Basal airway responsiveness but not allergic inflammation.Neutrophil and pathogen proteinases versus proteinase-activated receptor-2 lung epithelial cells: more terminators than activators.
P2860
Q24306707-7D28219E-3E58-40D9-83B6-632ED9BFC1BFQ24627446-6D9B94EE-2470-468F-AFB1-2D51CDB6D806Q24814725-4787CA6D-9F19-4DAC-B19D-5413E5E65FBCQ26747410-54D5BF1D-F664-4426-97B7-203956310EBEQ26825075-0A2668A8-88DE-4503-8C89-95164E6155CEQ26849305-C759872A-5D88-4A4D-BC6F-0CB8B1A38A8FQ26851156-65193F23-8305-4551-A48A-5937F568420FQ27305217-5F85AD2B-0C69-4852-91C3-242F8BB59AFCQ28237079-64578560-8D83-4D2E-9EAF-03E28C8BA840Q28276574-B1832DDA-90A5-4A81-9A24-A93B4D0B6B54Q28387389-331DE94D-20A2-4671-8CEA-E4728032039BQ33590029-A2892217-0739-4E6B-BE50-2154D3850FCEQ33658845-DC45A0F8-CE09-4F38-A28D-0EDE40789B6BQ33737245-A9351327-B4DB-485C-83BA-23280B5C5613Q34011439-8C36D0C9-359D-4AD1-B9E4-19CB48C6670EQ34011657-7262E845-135F-4953-9D35-B865B10F849CQ34046455-68244D90-BE74-4343-87DA-E419741DB38BQ34058334-DC01DCA5-821B-41CD-A842-928FA71231D5Q34067248-E91DEE86-31E7-4560-A508-23E0F14E7E66Q34374532-B6B09276-C25C-430C-ACFA-B0EEC2AFB28AQ34434995-4AAAECA1-A324-4095-8FE5-A5E2CADC5B12Q34598738-89705807-AB83-4317-B154-EBBC95900D3DQ34684607-BF9C5562-37D1-411D-B992-71905D558554Q34706829-342F5DE7-B5F5-4541-B44A-E9EE1DF5E7ECQ35000661-F62F72AE-D01A-4E8B-AFB2-EDCC4FBC5A03Q35048808-1E2854AA-23C7-4089-BFA0-116EF3A4EF8EQ35065919-38552BDE-E6C4-49DF-8B58-75E95FBCBF1CQ35095080-5D854228-557D-44AA-B19F-41C5321FFB71Q35543612-F30048D5-3890-4538-A349-92721CF33F3DQ35545787-F7523868-08DA-4838-999B-F6AE24276626Q35578642-3E169BFB-AE53-4E90-A304-BD6A12F3AAEDQ35811441-DA7BD860-A21F-4E26-B67B-23BB7F2E56BDQ35880228-25873EBC-2FE6-4EA4-8616-3C9104C48542Q36036213-93123534-AFCF-4595-BADF-B4B9123B1AECQ36168847-575DA4A4-929D-4BB9-AEB0-417E4FBCA4E7Q36180681-F630B746-8C1B-40A9-BAF5-8ADEE1A8505BQ36322131-530F8F5E-1757-40AD-A616-C05FF3F47538Q36375441-5E5BCA67-321F-418F-8A1F-54C7D42872D4Q36420377-E21DFF06-0D84-4ECB-BD47-068FF53BB243Q36425259-E417123B-B2B1-4A1F-A22B-103558DCAC11
P2860
The lung as a privileged site for the beneficial actions of PGE2.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The lung as a privileged site for the beneficial actions of PGE2.
@ast
The lung as a privileged site for the beneficial actions of PGE2.
@en
type
label
The lung as a privileged site for the beneficial actions of PGE2.
@ast
The lung as a privileged site for the beneficial actions of PGE2.
@en
prefLabel
The lung as a privileged site for the beneficial actions of PGE2.
@ast
The lung as a privileged site for the beneficial actions of PGE2.
@en
P50
P356
P1433
P1476
The lung as a privileged site for the beneficial actions of PGE2
@en
P2093
Claudio Mastruzzo
P356
10.1016/J.IT.2003.11.001
P577
2004-01-01T00:00:00Z